Hepatitis Monthly

Published by: Kowsar

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy

Pierre Pradat 1 , 2 , 3 , * , Victor Virlogeux 1 , 4 , Marianne Maynard 1 , 2 , 3 , Mathilde Leclercq 1 , Giorgiana Hatu 1 , 5 , Majid Amiri 1 , Fanny Lebosse 1 , 2 , 3 , Patrick Miailhes 6 , Fabien Zoulim 1 , 2 , 3 , 7 , Marie-Claude Gagnieu 8 and François Bailly 1 , 2 , 3
Authors Information
1 Department of Hepatology, Croix-Rousse Hospital, Hospices Civils of Lyon, Lyon, France
2 National Institute of Health and Medical Research (INSERM) U1052, Lyon, France
3 Claude Bernard Lyon 1 University, Lyon, France
4 Ecole Normale Superieure, Lyon, France
5 University of Medicine and Pharmacy, Cluj-Napoca, Romania
6 Department of Infectious Diseases and Tropical Medicine, Hospices Civils de Lyon, Lyon, France
7 Institut Universitaire of France, Paris, France
8 Department of Pharmacology, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France
Article information
  • Hepatitis Monthly: September 01, 2015, 15 (9); e28879
  • Published Online: September 1, 2015
  • Article Type: Brief Report
  • Received: March 30, 2015
  • Revised: March 31, 2015
  • Accepted: June 30, 2015
  • DOI: 10.5812/hepatmon.28879

To Cite: Pradat P, Virlogeux V, Maynard M, Leclercq M, Hatu G, et al. Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy, Hepat Mon. 2015 ; 15(9):e28879. doi: 10.5812/hepatmon.28879.

Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364(13): 1207-17[DOI][PubMed]
  • 2. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364(25): 2405-16[DOI][PubMed]
  • 3. Poordad F, McCone JJ, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364(13): 1195-206[DOI][PubMed]
  • 4. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011; 364(25): 2417-28[DOI][PubMed]
  • 5. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis. 1999; 19 Suppl 1: 17-24[PubMed]
  • 6. Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit. 2000; 22(5): 555-65[PubMed]
  • 7. Larrat S, Stanke-Labesque F, Plages A, Zarski JP, Bessard G, Souvignet C. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother. 2003; 47(1): 124-9[PubMed]
  • 8. Jen J, Laughlin M, Chung C, Heft S, Affrime MB, Gupta SK, et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther. 2002; 72(4): 349-61[DOI][PubMed]
  • 9. Sitole M, Silva M, Spooner L, Comee MK, Malloy M. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials. Clin Ther. 2013; 35(2): 190-7[DOI][PubMed]
  • 10. Sauvage FL, Stanke-Labesque F, Gagnieu MC, Jourdil JF, Babany G, Marquet P. Feasibility of ribavirin therapeutic drug monitoring in hepatitis C. Ther Drug Monit. 2009; 31(3): 374-81[DOI][PubMed]
  • 11. Preston SL, Drusano GL, Glue P, Nash J, Gupta SK, McNamara P. Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Agents Chemother. 1999; 43(10): 2451-6[PubMed]
  • 12. Cotte L, Barrail-Tran A, Vincent C, Valantin MA, Fournier I, Lacombe K, et al. Telaprevir enhances ribavirin-induced anaemia through renal function impairment. Antivir Ther. 2015; [DOI][PubMed]
  • 13. Kunze A, Huwyler J, Camenisch G, Gutmann H. Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochem Pharmacol. 2012; 84(8): 1096-102[DOI][PubMed]
  • 14. Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010; 298(4)[DOI][PubMed]
  • 15. Borroni G, Cazzaniga M, Andreoletti M, Ceriani R, Guerzoni P, Omazzi B, et al. Low glomerular filtration rate is a risk factor for ribavirin-associated anaemia in old patients with chronic hepatitis C. J Viral Hepat. 2013; 20(4)-5[DOI][PubMed]
  • 16. Russmann S, Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem. 2006; 13(27): 3351-7[PubMed]
  • 17. Alsio A, Rembeck K, Askarieh G, Christensen PB, Farkkila M, Langeland N, et al. Impact of obesity on the bioavailability of peginterferon-alpha2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3. PLoS One. 2012; 7(5)[DOI][PubMed]
  • 18. Wade JR, Snoeck E, Duff F, Lamb M, Jorga K. Pharmacokinetics of ribavirin in patients with hepatitis C virus. Br J Clin Pharmacol. 2006; 62(6): 710-4[DOI][PubMed]
  • 19. Summary of Product Characteristics. 2015;
  • 20. Glue P, Schenker S, Gupta S, Clement RP, Zambas D, Salfi M. The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. Br J Clin Pharmacol. 2000; 49(5): 417-21[PubMed]
  • 21. Takaki S, Tsubota A, Hosaka T, Akuta N, Someya T, Kobayashi M, et al. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol. 2004; 39(7): 668-73[DOI][PubMed]
  • 22. Hezode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014; 147(1): 132-142 e4[DOI][PubMed]
  • 23. Miailhes P, Gilbert C, Lacombe K, Arends JE, Puoti M, Rockstroh JK, et al. Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients. Liver Int. 2015; [DOI][PubMed]
  • 24. Brochot E, Bodeau S, Duverlie G. Does therapeutic drug monitoring of ribavirin in HCV genotype 3 treatment with sofosbuvir and ribavirin still have a role? Ther Drug Monit. 2015; 37(4): 550-1[DOI][PubMed]
  • 25. Pradat P, Virlogeux V, Gagnieu MC, Zoulim F, Bailly F. Ribavirin at the Era of Novel Direct Antiviral Agents for the Treatment of Hepatitis C Virus Infection: Relevance of Pharmacological Monitoring. Adv Hepatol. 2014; 2014: 1-13[DOI]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments